XML 37 R42.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 2 - Summary of Significant Accounting Policies (Details) (USD $)
3 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax   $ (2,795,705)us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax $ 955,535us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax $ 412,551us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
Foreign Currency Transaction Gain (Loss), before Tax   (554,241)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax 259,275us-gaap_ForeignCurrencyTransactionGainLossBeforeTax 200,452us-gaap_ForeignCurrencyTransactionGainLossBeforeTax
Allowance for Doubtful Accounts Receivable, Current   146,618us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent 593,023us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent  
Allowance for Doubtful Accounts Receivable, Write-offs   446,405us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs 0us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs 135,353us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs
Provision for Doubtful Accounts     238,071us-gaap_ProvisionForDoubtfulAccounts 135,353us-gaap_ProvisionForDoubtfulAccounts
Inventory, Net   12,406,776us-gaap_InventoryNet 10,996,785us-gaap_InventoryNet  
Inventory Adjustments   940,306us-gaap_InventoryAdjustments 758,106us-gaap_InventoryAdjustments  
Restructuring Costs and Asset Impairment Charges 2,500,000us-gaap_RestructuringCostsAndAssetImpairmentCharges      
Impairment of Long-Lived Assets to be Disposed of 300,000us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf      
Number of Reportable Segments   1us-gaap_NumberOfReportableSegments    
General and Administrative Expense [Member]        
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Provision for Doubtful Accounts   0us-gaap_ProvisionForDoubtfulAccounts
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember
255,564us-gaap_ProvisionForDoubtfulAccounts
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember
138,339us-gaap_ProvisionForDoubtfulAccounts
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_GeneralAndAdministrativeExpenseMember
Machinery and Equipment [Member] | Minimum [Member]        
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Property, Plant and Equipment, Useful Life   2 years    
Machinery and Equipment [Member] | Maximum [Member]        
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Property, Plant and Equipment, Useful Life   10 years    
Furniture and Fixtures [Member] | Minimum [Member]        
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Property, Plant and Equipment, Useful Life   5 years    
Furniture and Fixtures [Member] | Maximum [Member]        
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Property, Plant and Equipment, Useful Life   7 years    
DePuy Mitek, Inc., Medtronic Xomed, Soylu Medikal San ve Dis Tic Ltd., Rivex Pharma, and Takeda/Nycomed/Biomeks [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Concentration Risk, Percentage   74.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= anik_DePuyMitekIncMedtronicXomedSoyluMedikalSanVeDisTicLtdRivexPharmaAndTakedaNycomedBiomeksMember
67.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= anik_DePuyMitekIncMedtronicXomedSoyluMedikalSanVeDisTicLtdRivexPharmaAndTakedaNycomedBiomeksMember
 
In-process research & development [Member]        
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Restructuring Costs and Asset Impairment Charges       $ 1,200,000us-gaap_RestructuringCostsAndAssetImpairmentCharges
/ us-gaap_RestructuringCostAndReserveAxis
= anik_InProcessResearchDevelopmentMember
Minimum [Member]        
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Finite-Lived Intangible Asset, Useful Life   5 years    
Maximum [Member]        
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]        
Finite-Lived Intangible Asset, Useful Life   16 years